OncoC4, Inc.
PrivateLast Round
Series B
Oct 2, 2025
Est. Valuation
$660M
Total Funding Raised
$340M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
OncoC4, Inc. is a clinical-stage biotechnology company that discovers and develops novel biologics for the treatment of cancer and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OncoC4, Inc. Comparables
Compare OncoC4, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pheast Therapeutics | 81% | |
| Xilio Therapeutics | 81% | |
| Instil Bio | 81% |
OncoC4, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 2, 2025 | ||||
| Strategic | Mar 20, 2023 | ||||
| Convertible Debt | Apr 1, 2022 | ||||
| Series A | Dec 1, 2020 |
Key People
Founding team and executive leadership
OncoC4, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gobi Partners | Series B |
| HM Capital | Series B |
| Bencao Capital | Series B |
| Kaitai Capital | Series B |
| Greater Bay Area Homeland | Series B |
| HM Venture Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors increased 40% MoM, reaching 6.1K.
- Jan 20, 2026
Monthly visitors grew 191% MoM, reaching 7.4K.
Recent news
Latest coverage and updates
- hiresSep 1, 2026
OncoC4, Inc. hired Chen as General Counsel on Sep 1st '26.
- partners_withSep 1, 2026
OncoC4, Inc. partnered with BioNTech SE on Mar 1st '23.
- hiresSep 1, 2026
OncoC4, Inc. hired Steve Chen as General Counsel on Sep 1st '26.
- is_developingAug 17, 2026
OncoC4, Inc. is developing several first-in-class cancer treatments based on the neoCD24 platform.
OncoC4, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about OncoC4, Inc.'s valuation, stock price, and market status.
Is OncoC4, Inc. a public or private company?
OncoC4, Inc. is a private company.
What is the current stock price of OncoC4, Inc.?
OncoC4, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is OncoC4, Inc. worth (valuation)?
OncoC4, Inc.'s valuation is estimated at $660.0M based on funding round data.
Can I buy OncoC4, Inc. stock?
OncoC4, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was OncoC4, Inc.'s last funding round?
OncoC4, Inc.'s most recent funding round was Series B on October 2, 2025.
Who are the main investors in OncoC4, Inc.?
Key investors in OncoC4, Inc. include Greater Bay Area Homeland.
Will OncoC4, Inc. IPO soon?
No public IPO plans have been announced for OncoC4, Inc..
How can I track OncoC4, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor OncoC4, Inc.'s secondary market activity and sign up for updates.